title: Fibronectin, cholesterol and triglycerides ascitic fluid concentration in the prediction of malignancy.
abstract: There have been few trials comparing the efficacy of determinations of cholesterol, fibronectin and triglycerides for diagnosis of malignant ascites. In this study we measured these in 200 ascitic fluids from 93 cirrhotic patients (Group A), 47 hepatocellular-carcinoma patients (Group B), 60 extra-hepatic tumour patients (Group C), 44 of them with malignant cells (Group Cpos) and 16 without (Group Cneg). Anova one-way and the Bonferroni test for multiple comparisons showed that fibronectin and cholesterol were significantly higher in the ascitic fluids of patients of group C than of groups A and B (mean +/- ESM) (Cholesterol in A: 27.2 +/- 2.8; in B 23.5 +/- 1.5; in C: 68.6 +/- 5.3 mg/dl. Fibronectin in A: 32.7 +/- 2.8; in B 31.3 +/- 2.6; in C 127.7 +/- 11.1 mg/l). Both were significantly higher in Group Cpos than in Group Cneg (Cholesterol in Cneg: 41.2 +/- 6.7; in Cpos: 78.6 +/- 6.2 mg/dl. Fibronectin in Cneg: 55.0 +/- 11.2; in Cpos 154 +/- 12.3 mg/dl). We found no differences between cirrhotic ascites and malignant ascites due to primary liver hepatocellular-carcinoma. No difference at all in triglycerides were detected. With the Receiver-Operating Characteristic (ROC) curve, cholesterol had the best Youden Index (57%) at a cut-off of 32 mg/dl (sensitivity 78.3%, specificity 79.3% at this level); the best Youden Index (64%) for fibronectin had a cut-off of 60 mg/dl (sensitivity 65%, specificity 89.3%). Triglycerides appeared to be a great deal less effective as a diagnostic marker, with their best Youden Index (23%) at a cut-off 32 mg/dl (sensitivity 66.7%, specificity 56.4%).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Istituto di Medicina Interna e Laboratori, Ospedale Bolognini, Seriate, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Colloredo Mels
authors.forename: G
authors.initials: G
authors.lastname: Bellati
authors.forename: L
authors.initials: L
authors.lastname: Auriemma
authors.forename: C
authors.initials: C
authors.lastname: Perani
authors.forename: G
authors.initials: G
authors.lastname: Leandro
authors.forename: N
authors.initials: N
authors.lastname: Vacca
authors.forename: N
authors.initials: N
authors.lastname: Pinna
authors.forename: G
authors.initials: G
authors.lastname: Alfieri
authors.forename: G
authors.initials: G
authors.lastname: Ideo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001202:Ascitic Fluid / Q000737:chemistry*; D014408:Biomarkers, Tumor / Q000032:analysis*; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis*; D002648:Child; D002784:Cholesterol / Q000032:analysis*; D003937:Diagnosis, Differential; D005260:Female; D005353:Fibronectins / Q000032:analysis*; D006801:Humans; D008103:Liver Cirrhosis / Q000175:diagnosis*; D008113:Liver Neoplasms / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D012372:ROC Curve; D012680:Sensitivity and Specificity; D014280:Triglycerides / Q000032:analysis*
chemical_list: D014408:Biomarkers, Tumor; D005353:Fibronectins; D014280:Triglycerides; D002784:Cholesterol